In our patient imiquimod 3.75% cream showed an acceptable tolerability profile with the advantage of being self-applied by the patient, showing an efficacy not only at the level of actinic keratosis and NMSCs, but also in case SL. Further studies are necessary to validate theuse of imiquimod also for benign skin lesions, associated with chronic skin photodamage.
Clinical evaluation and efficacy of Imiquimod 3.75% cream for the treatment of actinic keratosis, pigmented basal cell carcinomas and actinic cheilitis / Paolino, G; Cantoresi, F; Mercuri, S R; Cantisani, C. - In: DERMATOLOGIC THERAPY. - ISSN 1396-0296. - 33:3(2020). [10.1111/dth.13356]
Clinical evaluation and efficacy of Imiquimod 3.75% cream for the treatment of actinic keratosis, pigmented basal cell carcinomas and actinic cheilitis
Paolino, G;Cantoresi, F;Cantisani, C
2020
Abstract
In our patient imiquimod 3.75% cream showed an acceptable tolerability profile with the advantage of being self-applied by the patient, showing an efficacy not only at the level of actinic keratosis and NMSCs, but also in case SL. Further studies are necessary to validate theuse of imiquimod also for benign skin lesions, associated with chronic skin photodamage.| File | Dimensione | Formato | |
|---|---|---|---|
|
Paolino_Clinical_2020.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
575.52 kB
Formato
Adobe PDF
|
575.52 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
